



NDA 19-386/S-019 & S-020

Baxter Healthcare Corporation, Anesthesia & Critical Care
Attention: Ms. Priya Jambhekar
95 Spring Street
New Providence, NJ 07974

Dear Ms. Jambhekar:

Please refer to your supplemental new drug applications dated September 30, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Brevibloc Premixed Injection (esmolol hydrochloride) 10 mg/mL in 250mL Bags (S-019) and Brevibloc Double Strength Premixed Injection (esmolol hydrochloride) 20mg/mL in 100mL Containers (S-020).

We acknowledge receipt of your submission dated January 13, 2003.

These supplemental new drug applications provide for changes to the currently approved NDA 19-386. Supplement 019 represents the completion of a phase 4 commitment which was agreed upon by Baxter Healthcare Corporation, Anesthesia & Critical Care with the approval of a supplemental application, S-018, for Brevibloc Premixed Injection 10mg/mL packaged in 250 mL Bags on February 16, 2001. The commitment was as follows:

Baxter PPI makes a post-approval commitment to reevaluate the subject formulation to either eliminate or significantly reduce overage of esmolol HCl added in the formulation, and submit it as a supplement. The detailed plans of action will be submitted by August 2001 for the Brevibloc Premixed Injection and by February 2002 for the Brevibloc Concentrate. At the time you submit your plans, please include a date that the supplement(s) will be submitted.

Supplement 019 includes the reformulation of the Premixed Injection to reduce overage of the active from 10% to 4%. In addition, it includes a change in the text on the bags from red to lavender. Supplement 020 is to market a new formulation, Brevibloc Double Strength Premixed Injection in a ready-to-use 100mL PL-2084 plastic bag with dual ports, containing 20 mg/mL concentration of esmolol HCl.

These supplements propose the following changes to the package insert:

1. The addition of the following to the title of the package insert:

BREVIBLOC PREMIXED INJECTION
(Esmolol Hydrochloride)
DOUBLE STRENGTH
Ready-to-use Bags
100 mL Bags
Iso-Osmotic Solution of Esmolol Hydrochloride in Sodium Chloride
For Intravenous Use

Esmolol Hydrochloride concentration = 20 milligrams/mL (20,000 micrograms/mL)

Single Patient Use Only

No Preservatives Added

2. The addition of the following line to the title under the **BREVIBLOC INJECTION**, Ready-to-use Vials, 10mL Vials:

Iso-Osmotic Solution of Esmolol Hydrochloride in Sodium Chloride

3. The addition of the following paragraph at the end of the **DESCRIPTION** section, **Brevibloc Premixed Injection** subsection:

2000 mg, 100 mL Single Use Premixed Bag DOUBLE STRENGTH – Each mL contains 20 mg Esmolol Hydrochloride, 4.1 mg Sodium Chloride, USP and Water for Injection, USP; buffered with 2.8 mg Sodium Acetate Trihydrate, USP and 0.546 mg Glacial Acetic Acid, USP. Sodium Hydroxide and/or Hydrochloric Acid added, as necessary, to adjust pH to 5.0 (4.5-5.5). The calculated osmolarity is 312mOsmol/L. The 100 mL bag is non-latex, non-PVC IntraVia bag with dual PVC ports. The IntraVia bag is manufactured from a specially designed multilayer plastic (PL 2408). Solutions in contact with the plastic container leach out certain chemical compounds from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. See **DOSAGE AND ADMINISTRATION, Directions for Use of the Premixed Bag** for additional information.

4. The **DESCRIPTION/Brevibloc Injection** subsection has been changed from:

BREVIBLOC INJECTION is a clear, colorless to light yellow, sterile, nonpyrogenic solution.

100 mg, 10 mL Single Dose Vial – Each mL contains 10 mg Esmolol Hydrochloride and Water for Injection, USP; buffered with 2.8 mg Sodium Acetate Trihydrate, USP and 0.546 mg Glacial Acetic Acid, USP. Sodium Hydroxide and/or Hydrochloric Acid added, as necessary to adjust pH to 4.5-5.5.

To:

BREVIBLOC INJECTION is a clear, colorless to light yellow, sterile, nonpyrogenic, iso-osmotic solution of esmolol hydrochloride in sodium chloride.

100 mg, 10 mL Single Dose Vial – Each mL contains 10 mg Esmolol Hydrochloride, 5.9 mg Sodium Chloride, USP and Water for Injection, USP; buffered with 2.8 mg Sodium Acetate Trihydrate, USP and 0.546 mg Glacial Acetic Acid, USP. Sodium Hydroxide and/or Hydrochloric Acid added, as necessary to adjust pH to 5.0 (4.5-5.5).

5. Under the **DOSAGE AND ADMINISTRATION** section, the subsection heading has been changed from:

Directions for Use of Brevibloc Premixed Injection

To:

Directions for Use of Brevibloc Premixed Injection and Brevibloc Premixed Injection DOUBLE STRENGTH

6. Under the **DOSAGE AND ADMINISTRATION/Directions for Use of Brevibloc Premixed Injection and Brevibloc Premixed Injection DOUBLE STRENGTH** subsection, the paragraph has been

This dosage form is prediluted to 250 mL to provide a ready-to-use, iso-osmotic solution of 10 mg/mL esmolol hydrochloride in sodium chloride. Do not introduce additives to BREVIBLOC PREMIXED INJECTION. See **Directions for Use of the Premixed Bag** for additional information.

To:

This dosage form is prediluted to 100 or 250 mL to provide a ready-to-use, iso-osmotic solution of 20 or 10 mg/mL esmolol hydrochloride in sodium chloride. Do not introduce additives to BREVIBLOC PREMIXED INJECTION or BREVIBLOC PREMIXED INJECTION DOUBLE STRENGTH. See **Directions for Use of the Premixed Bag** for additional information.

7. Under the **DOSAGE AND ADMINISTRATION/Directions for Use of the Premixed Bag** subsection, the first sentence has been changed from:

BREVIBLOC PREMIXED INJECTION is provided in 250 mL IntraVia bags, which are ready-to-use, non-latex, non-PVC bags with two ports, a medication port and a delivery port.

To:

BREVIBLOC PREMIXED INJECTION and BREVIBLOC PREMIXED INJECTION – DOUBLE STRENGTH are provided in 250 mL and 100 mL IntraVia bags, which are ready-to-use, non-latex, non-PVC bags with two ports, a medication port and a delivery port.

8. The following paragraph was added to the end of the **DOSAGE AND ADMINISTRATION/Directions for Use of the Premixed Bag** subsection:

The Brevibloc Premixed Injection DOUBLE STRENGTH contains Esmolol Hydrochloride at a concentration of 20 milligrams/mL. When using 20 milligrams/mL concentration, a loading dose of 0.5 milligrams/kg infused over 1 minute period of time, for a 70 kg patient, is 1.75 mL. The loading dose can be removed from the medication port of the premixed bag.

9. In Figure 1. Two-Port IntraVia Bag, the text to describe the two ports, “Medication Port (for withdrawing initial bolus)” and “Delivery Port”, was deleted.

10. In the **DOSAGE AND ADMINISTRATION/Directions for Use of the Premixed Bag** subsection, the last sentence under the directions TO OPEN has been changed from:

Do not introduce additives to BREVIBLOC PREMIXED INJECTION.

To:

Do not introduce additives to BREVIBLOC PREMIXED INJECTION or BREVIBLOC PREMIXED INJECTION – DOUBLE STRENGTH.

11. The first sentence under the **DOSAGE AND ADMINISTRATION/Directions for Use of the 10 mL Ready-to-use Vial (10 milligrams/mL)** subsection has been changed from:

This dosage form is prediluted to provide a ready to use 10mg/mL concentration recommended for BREVIBLOC intravenous administration.

To:

This dosage form is prediluted to provide a ready-to-use, iso-osmotic solution of 10mg/mL esmolol hydrochloride in sodium chloride recommended for BREVIBLOC intravenous administration.

12. The following has been added to the **HOW SUPPLIED** section:

BREVIBLOC PREMIXED INJECTION – DOUBLE STRENGTH
NDC 10019-075-87, 2000 MG – 100 MI IntraVia Bags

13. The description of the BREVIBLOC INJECTION in the **HOW SUPPLIED** section has been changed from:

NDC 10019-015-01, 100 mg – 10 mL Ready-to-use Vials, Box of 20

To:

NDC 10019-115-01, 100 mg – 10 mL Ready-to-use Vials, Package of 25

NDA 19-386/S-019 proposes the following changes to the container labeling:

Immediate Plastic Bag Labeling

1. The color of the text of the Lot/Exp, NDC number, Product Name, and strength has been changed from bright red to lavender.

Foil Pouch Labeling

1. The manufacturing code and product code located on the bottom right hand corner above the number for product inquiries have been changed from:

2J1404
460-250-00
7-7-10-978
2000/8

To:

2J1415
460-370-00
7-7-31-553
2000/8

2. The addition of text on the back of the foil pouch including the product name and strength in lavender.

NDA 19-386/S-020 proposes the following new container labeling, as compared to the current single strength labeling:

Transfer Label

1. The product name will appear in sea foam green as opposed to lavender.
2. The potency will read 20mg/mL instead of 10mg mL.

4. The product name will read Brevibloc DOUBLE STRENGTH Premixed Injection rather than Brevibloc Premixed Injection.
5. The manufacture code will be 7-00-00-000 instead of 7-09-18-925.

20mg/mL in 100 mL Bag

1. The product name will appear in sea foam green as opposed to bright red.
2. The NDC code will read 10019-075-87 instead of 10019-055-61.
3. The product name will read Brevibloc DOUBLE STRENGTH Premixed Injection rather than Brevibloc Premixed Injection.
4. The strength will read 2,000mg/100mL (20mg/mL) not 2,500mg/250mL (10mg/mL).
5. The contents will read “Each mL contains 20mg esmolol hydrochloride, 4.1 mg sodium chloride USP in water for injection USP. Buffered with 2.8 mg sodium acetate trihydrate USP and 0.546 mg glacial acetic acid USP pH adjusted with sodium hydroxide and/or hydrochloric acid pH 5.0 (4.5-5.5) Sterile nonpyrogenic”. This is instead of 10mg esmolol hydrochloride, 5.9 mg sodium chloride USP as in the single strength; all other wording is unchanged.
6. The component code will be 460-324-00 instead of 460-249-00.
7. The manufacturing code, internal tracking number will be 2J1413 instead of 2J1404.

Foil Pouch Labeling

1. The product name will appear in sea foam green as opposed to lavender.
2. The NDC code will read 10019-075-87 instead of 10019-055-61.
3. The product name will read Brevibloc DOUBLE STRENGTH Premixed Injection rather than Brevibloc Premixed Injection.
4. The strength will read 2,000mg/100mL (20mg/mL) instead of 2,500mg/250mL (10mg/mL).
5. The contents will read “Each mL contains 20mg esmolol hydrochloride, 4.1 mg sodium chloride USP in water for injection USP. Buffered with 2.8 mg sodium acetate trihydrate USP and 0.546 mg glacial acetic acid USP pH adjusted with sodium hydroxide and/or hydrochloric acid pH 5.0 (4.5-5.5) Sterile nonpyrogenic”. This is instead of 10mg esmolol hydrochloride, 5.9 mg sodium chloride USP as in the single strength; all other wording is unchanged.
6. The component code has changed to 2J1413; 460-371-00; 7-7-31-552 instead of 2J1404; 460-250-00; 7-7-10-978.
7. A product identification is to be added to the back of the pouch in seafoam green with product name and strength.

We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.